Researchers in the UK found that most children with juvenile idiopathic arthritis (JIA) are receiving synthetic disease-modifying antirheumatic drugs (DMARDs, 58%) and/or biologics (20%), usually in combination with steroid treatment. The most commonly prescribed first-line biologic was etanercept (83% of the patients) followed by infliximab (9%) and adalimumab (5%).

Click here for more.